{
    "clinical_study": {
        "@rank": "165037", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.   Evaluate the efficacy of tin mesoporphyrin in patients with acute porphyria\n      attacks who are also treated with a standard course of heme arginate.\n\n      II.  Evaluate the safety and tolerability of tin mesoporphyrin when administered to these\n      patients."
        }, 
        "brief_title": "Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria", 
        "completion_date": "May 2000", 
        "condition": "Porphyria", 
        "condition_browse": {
            "mesh_term": [
                "Porphyrias", 
                "Porphyria, Erythropoietic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is an randomized, unblinded, multicenter study. Patients are\n      randomized to receive heme arginate alone or both heme arginate and tin mesoporphyrin.\n\n      Patients receive a single intravenous dose of tin mesoporphyrin immediately before the first\n      dose of heme arginate.  Heme arginate is administered daily for 4 days.\n\n      Patients are followed at 3 and 6 days after treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Documented acute intermittent porphyria, variegate porphyria, or hereditary coproporphyria\n\n        No chronic or subacute symptoms (present for longer than 2 weeks)\n\n        --Prior/Concurrent Therapy--\n\n        At least 3 weeks since prior treatment with heme arginate or tin mesoporphyrin\n\n        --Patient Characteristics--\n\n        Renal: Urinary porphobilinogen at least 40 mg/24 hr\n\n        Other:\n\n          -  Not pregnant\n\n          -  Fertile female patients must use effective contraception during and 6 months before\n             study\n\n          -  No evidence that symptoms are due to another acute illness\n\n          -  No acute hemorrhagic disorder such as: Gastrointestinal bleeding Intracerebral\n             hemorrhage\n\n          -  No known sensitivity to heme preparation or tin mesoporphyrin\n\n          -  No other medical condition that might increase risk to patient"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "24", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004398", 
            "org_study_id": "199/13191", 
            "secondary_id": [
                "UTMB-97-118", 
                "UTMB-FDR001459"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "heme arginate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "tin mesoporphyrin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tin mesoporphyrin"
        }, 
        "keyword": [
            "inborn errors of metabolism", 
            "porphyria", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Texas", 
            "last_name": "Karl Elmo Anderson", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004398"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Texas", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 1998", 
        "study_design": "Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2000"
    }, 
    "geocoordinates": {}
}